Clinical trials: Adjustment Disorder
Venous Thromboembolism
EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis
The purpose of this study is to evaluate comparative efficacy and safety of rivaroxaban to standard of care in children with acute venous thromboembolism.
- Trial name
- EINSTEIN Jr (NCT02234843)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
- Where
- 109 sites in United States, Argentina and 26 more
- Volunteers
- 500 people
- Sponsor
- Bayer
Non-Hodgkin's Lymphoma
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
About 60% of patients with DLBCL can be cured with a chemotherapy program. It is called RCHOP-21 (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone). It is given once every 3 weeks, for 18 weeks.
- Trial name
- NCT00712582
- Testing
- Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin, Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diabetes, Diabetes Mellitus, Type 2
Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes
This trial was conducted in Asia, Europe and South America. The aim of this trial was to confirm efficacy of subject driven titration (individually adjusted) of biphasic insulin aspart 30 (BIAsp 30) twice daily in terms of…
- Trial name
- SimpleMix™ (NCT01427920)
- Testing
- biphasic insulin aspart 30
- Where
- 41 sites in Argentina, China and 4 more
- Volunteers
- 348 people
- Sponsor
- Novo Nordisk A/S
Leukemia-Lymphoma, Adult T-Cell
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
The rationale of the current study is to explore the use of combination chemotherapy together with antiretroviral agents in order to determine the efficacy and toxicity of this approach, while also examining markers of virus…
- Trial name
- ATLL (NCT01000285)
- Testing
- Bortezomib, Etoposide, Vincristine
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Burkitt Lymphoma, High-grade B-cell Lymphoma
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
Background: Burkitt Lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) are aggressive B cell lymphomas. Frontline treatment does not always work. Researchers want to see if a combination of drugs can help.
- Conditions
- Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL)
- Trial name
- NCT04933617
- Testing
- Rituximab, Etoposide, Copanlisib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Psychosis
USS Training to Improve Social Function in People With Psychosis
Psychotic spectrum disorders (PSD) are associated with poor social function. By doing this study, the investigators hope to learn which of two different types of 2-month long training courses is more effective in improving…
- Trial name
- NCT04557124
- Testing
- USS, MovingForward
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- VA Office of Research and Development
Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Background: Burkitt lymphoma/leukemia (BL) is highly treatable, but most of the standard therapies require multiple doses of intensive chemotherapy that may require long hospital stays and frequently have severe side effects.
- Conditions
- Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma
- Trial name
- NCT01092182
- Testing
- EPOCH-R, EPOCH-RR
- Where
- 30 sites in United States
- Volunteers
- 194 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen
RATIONALE: Giving chemotherapy, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- LCCC0510 (NCT00448357)
- Testing
- rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hepatitis C, Medication Adherence
Intensive Models of HCV Care for Injection Drug Users
Injection drug users (IDUs) constitute 60% of the approximately 5 million people in the U.S. infected with hepatitis C virus (HCV). HCV treatment leading to sustained viral response (SVR) is associated with increased survival.
- Trial name
- NCT01857245
- Testing
- Intensive Models (mDOT and CGT) of HCV Care
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Prisma Health-Upstate
Colorectal Cancer, Gastric Cancer
Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy
The study is testing an intervention of an investigator-developed chemotherapy dose adjustment algorithm. The primary objective of this study is to evaluate the effectiveness of the chemotherapy dose adjustment algorithm for…
- Conditions
- Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ampullary Cancer
- Trial name
- NCT04526886
- Testing
- Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Atrial Fibrillation
Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
The investigators' central hypothesis is that in patients with atrial fibrillation, anticoagulation with Apixaban reduces the rate of decline in cognitive function, when compared to Warfarin.
- Trial name
- ARISTA (NCT03839355)
- Testing
- Apixaban, Warfarin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Oropharyngeal Cancer
De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
The purpose of this study is to find out whether radiotherapy to some of the lymph node areas can be safely omitted to decrease side effects without increasing the risk of the tumour coming back.
- Trial name
- EVADER (NCT03822897)
- Testing
- Radiation, Cisplatin
- Where
- 14 sites in Canada
- Volunteers
- 103 people
- Sponsor
- Canadian Cancer Trials Group
Cerebral Atherosclerosis
Clinical Trial of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis
The purpose of this study is to obtain additional data on efficacy and safety of Divaza for adjustment of oxidative disorders in patients with cerebral atherosclerosis.
- Trial name
- NCT03485495
- Testing
- Divaza
- Where
- 10 sites in Russia
- Volunteers
- 124 people
- Sponsor
- Materia Medica Holding
Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma
PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer
This phase II trial studies how well intensity modulated radiation therapy adjusted by positron emission tomography (PET) scanning together with combination chemotherapy works in treating patients with stage II-IV non-small cell…
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
- Trial name
- PAINT (NCT02073968)
- Testing
- Carboplatin, Computed Tomography, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Albert Einstein College of Medicine
Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
This is a Phase 1b/2, open-label, non-randomized multicenter study to assess the safety and efficacy of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with relapsed/refractory Diffuse Large B-cell Lymphoma…
- Trial name
- NCT02142049
- Testing
- Ibrutinib, DA-EPOCH-R, Lenalidomide
- Where
- 10 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pharmacyclics LLC.
Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)
The purpose of this study is to evaluate the safety profile of orally administered tapentadol ER dosages of 100 to 250 mg twice daily in patients with chronic, painful diabetic peripheral neuropathy (DPN) over long-term exposure…
- Trial name
- NCT01063868
- Testing
- Tapentadol extended release (ER), Oxycodone controlled release (CR)
- Where
- 23 sites in United States
- Volunteers
- 47 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Traumatic Brain Injury
Intervention to Promote Survivor Resilience and Adjustment: Efficacy and Sustainability
The aims of this traumatic brain injury (TBI) study are: 1. to evaluate the short and long-term efficacy of two structured outpatient intervention programs, Resilience and Adjustment Intervention (RAI) vs.
- Trial name
- NCT03421964
- Testing
- Resilience/Adjustment Counseling, Resilience/Adjustment Counseling with Booster Sessions
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- Virginia Commonwealth University
Leukemia, Myeloid, Chronic-Phase
Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response
The Imatinib Mesylate at a dose of 400 mg / day is the standard treatment for patients with CML-CP. Recent studies show that the quality of response rate (complete cytogenetic response and major molecular response rate) is…
- Trial name
- MIM (NCT01827930)
- Testing
- Imatinib Mesylate 600 MG Oral Tablet, Imatinib Mesylate 400 MG Oral Tablet, Imatinib Mesylate
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Institut Bergonié
Acute Myeloid Leukemia
A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1b/2a multi-center, open-label, non-randomized study to assess the safety, tolerability and efficacy of dose-adjusted brequinar in adult subjects with acute myeloid leukemia (AML).
- Trial name
- NCT03760666
- Testing
- Brequinar/Brequinar + Ribavirin
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Clear Creek Bio, Inc.
Cardiovascular Disease, Type 2 Diabetes
Physical Health in Midlife: Influences of Adversity and Relationships Over Time
The purpose of this study is to determine the effects of individual characteristics, life stresses, and relationships over time on psychosocial outcomes (e.g. marriage, parenting, work) and physical health
- Trial name
- NCT01853332
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Beth Israel Deaconess Medical Center